Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection

Airways of Cystic Fibrosis (CF) patients are Nitric Oxide (NO) deficient which may contribute to impaired lung function and infection clearance. Mycobacterium abscessus (M. abscessus) infection prevalence is increasing in CF patients and is associated with increased morbidity and mortality. Here, we assess the safety and efficacy of intermittent inhaled NO (iNO) as adjuvant therapy in CF patients with refractory M. abscessus lung infection.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research

Related Links:

Authors: Sarti F, Wolf K, Talsma J, Pierce-Talsma S PMID: 31233115 [PubMed - in process]
Source: Journal of the American Osteopathic Association - Category: Complementary Medicine Tags: J Am Osteopath Assoc Source Type: research
Conclusion: These findings support the use of OMT as a method for the management of chronic constipation and DIOS in the CF population. However, because of the small population size, more research with larger populations is needed. PMID: 31233114 [PubMed - in process]
Source: Journal of the American Osteopathic Association - Category: Complementary Medicine Tags: J Am Osteopath Assoc Source Type: research
Authors: Gomes DC, Longo E, de Camargo OK, de Sousa Dantas D, Ferreira HN, Regalado ICR, Ribeiro LC, Pereira SA Abstract OBJECTIVE: To identify the most common quality of life instruments for children with cystic fibrosis and link the content with the International Classification of Functioning, Disability and Health (ICF). METHODS: The study was conducted in 2 stages. The first stage involved a review of the literature to select quality of life questionnaires. In the second stage 2 independent reviewers identified questionnaire items and categories corresponding to the ICF, according to approved methodology. T...
Source: Journal of Rehabilitation Medicine - Category: Rehabilitation Tags: J Rehabil Med Source Type: research
(Cleveland Clinic) Implemented in 2005, the lung allocation score is used to prioritize patients awaiting lung transplants in the US. Sicker transplant candidates have a higher calculated score and are placed at the top of the list. But a recent study led by Maryam Valapour, M.D., MPP, director of Lung Transplant Outcomes in Cleveland Clinic's Respiratory Institute, found including new clinical variables helped to better identify the sickest cystic fibrosis and chronic obstructive pulmonary disease patients awaiting transplants.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, FDA Approvals, Source Type: news
MONDAY, June 24, 2019 -- The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. Food and Drug...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Corinne McKay says she'd always wanted to see Machu Picchu, and while the 57-year-old has cystic fibrosis, she said she figured she was healthy enough to do the trek now. So she did.
Source: CBC | Health - Category: Consumer Health News Tags: News/Canada/Saskatchewan Source Type: news
Conclusion: An electronic alert incorporated into the ED workflow to populate a discharge order set is effective to initiate asthma controller medication for poorly controlled pediatric patients. Additional data describing reasons for not prescribing ICS can further refine recommendations for ICS prescriptions, and provide a comprehensive strategy to support clinical decision for pediatric asthma control in acute care settings. PMID: 31226000 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
FDA expanded the indication for Symdeko for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Discussion –-       Bronchial atresia usually is benign and asymptomatic and is incidental finding&clinical manifestations may range from recurrent pulmonary infections to mild wheezing and dyspnea. Bronchial atresia is a congenital abnormality resulting from focal interruption of a lobar, segmental, or subsegmental bronchus with associated peripheral mucus impaction (bronchocele, mucocele) and associated hyperinflation of the obstructed lung segment. The apicoposterior segmental bronchus of the left upper lobe is most common site to be involved, followed by segmental bronc...
Source: Sumer's Radiology Site - Category: Radiology Authors: Source Type: blogs
More News: Cystic Fibrosis | Respiratory Medicine | Study